Week 3 I was cleared to up the dose a bit so I did

[4] [5] Appropriate clinical management for patients with comorbid metabolic conditions and problematic alcohol use should include: Comprehensive assessment of alcohol consumption patterns using validated screening tools (AUDIT, AUDIT-C) Referral to addiction medicine specialists or behavioral health providers for evidence-based AUD treatment, especially with red flags such as history of severe withdrawal, seizures, delirium tremens, pregnancy, severe liver disease, or suicidality Consideration of FDA-approved pharmacotherapies for alcohol use disorder (naltrexone, acamprosate, disulfiram) with attention to their specific contraindications [9] [11] If GLP-1 therapy is indicated for diabetes or obesity, close monitoring for changes in alcohol consumption and related behaviors Patient education emphasizing that any effects on alcohol cravings are not established therapeutic benefits Regular follow-up to assess medication adherence, adverse effects, and overall treatment response Patients should never discontinue evidence-based treatments for alcohol use disorder in favor of unproven approaches

We discovered that platypus and echidna express a single GLP-1 peptide in both intestine and venom
But when food intake is limited, prioritizing soluble fiber tends to produce better results because it directly addresses the primary problem, stool that has become too hard and dry
GLP-1 medications affect how your body processes food and beverages, and many patients find their alcohol tolerance decreases significantly